Rekombinanter SARS-CoV-2 Spike S1 Antikörper (RBD)
-
- Target Alle SARS-CoV-2 Spike S1 Antikörper anzeigen
- SARS-CoV-2 Spike S1
- Antikörpertyp
- Recombinant Antibody
-
Bindungsspezifität
- RBD
-
Reaktivität
- SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV)
-
Wirt
-
Human
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser SARS-CoV-2 Spike S1 Antikörper ist unkonjugiert
-
Applikation
- ELISA, Immunofluorescence (IF), Crystallization (Crys), Surface Plasmon Resonance (SPR)
- Verwendungszweck
- Recombinant monoclonal antibody to COVID-19 & SARS-CoV S glycoprotein.
- Spezifität
-
The antibody CR3022 binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318-510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" conformation of the spike protein (Joyce et al. 2020).
While most S-protein RBD binding antibodies compete for antigen binding with ACE2, the CR3022 epitope does not overlap with the ACE2-binding site. It does thus not hinder binding of neutralizing antibodies. While CR3022 on its own exhibits only a weak neutralizing effect, it has been shown to synergize with other S-protein RBD binding antibodies to neutralize SARS-CoV. This effect still has to be confirmed in context with SARS-CoV-2 (Yuan et al. 2020).
- Kreuzreaktivität (Details)
- The anti-SARS-CoV-2 antibody CR3022 was originally discovered in a SARS patient, but it was shown to be a potent binder of SARS-CoV-2 spike protein (S1).
- Produktmerkmale
-
Original Species of Ab: Human
Original Format of Ab: IgG1
- Aufreinigung
- Affinity Purified using a recombinant lectin column
- Immunogen
- The original monoclonal antibody was generated through an scFv library derived from a peripheral blood lymphocytes of a patient exposed to the SARS-CoV.
- Klon
- CR3022
- Isotyp
- IgM kappa
- Top Product
- Discover our top product SARS-CoV-2 Spike S1 Primärantikörper
-
-
- Applikationshinweise
- This antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 < a href="https://www.medrxiv.org/content/10.1101/2020.03.17.20037713v1" target="_blank">(Amanat et al. 2020). Human IgG2 and IgG4 subtypes, which are also seen in a small subset of COVID-19 patients, are also available to investigate their role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-ompeting SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020). Bates et al. 2021 (PMID: 32766589) used CR3022 in a immunofluorescence assay.
- Kommentare
-
This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 1 mg/mL
- Buffer
- PBS with 0.02 % Proclin 300.
- Konservierungsmittel
- ProClin
- Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
- Target
- SARS-CoV-2 Spike S1
- Abstract
- SARS-CoV-2 Spike S1 Produkte
- Substanzklasse
- Viral Protein
- Hintergrund
- Spike protein, COVID19, COVID 19, S protein, SARS-CoV S protein, S glycoprotein, E2, Peplomer protein, Spike protein S1, SARS Coronavirus, SARS-CoV-2, SARS CoV 2, 2019-nCoV, Ab1680.10, Ab1680.15, Ab1680.16
- UniProt
- P59594
-